A recent report described a patient with a JAK2V617F-positive PMF and an inherited GATA2 mutation who developed a basal cell carcinoma of the facial skin six years after the initial diagnosis and therapy with the JAK inhibitor ruxolitinib [57]. The gene discussed is GATA2; the disease is basal cell carcinoma.